Experienced in Febrile Neutropenia

Dr. Dale G. Schaar

Oncology
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 
Experienced in Febrile Neutropenia
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dale Schaar is an Oncologist in New Brunswick, New Jersey. Dr. Schaar is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Robert Wood Johnson University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM
195 Little Albany St, New Brunswick, NJ 08901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: December 08, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Venetoclax, Liposomal Vincristine
Study Phase: Phase 1/Phase 2
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: Belinostat, Pevonedistat
Study Phase: Phase 1
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Terminated
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

13 Total Publications

Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant.
Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant.
Journal: Transplant infectious disease : an official journal of the Transplantation Society
Published: September 25, 2024
Similar Doctors
Distinguished in Febrile Neutropenia
Dr. Dawn L. Hershman
Oncology
Distinguished in Febrile Neutropenia
Dr. Dawn L. Hershman
Oncology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (35.6 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dawn Hershman is an Oncologist in New York, New York. Dr. Hershman is rated as an Elite provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Breast Cancer, Febrile Neutropenia, Inflammatory Breast Cancer, Vulvectomy, and Hormone Replacement Therapy (HRT).

Lindsay R. Wilde
Distinguished in Febrile Neutropenia
Dr. Lindsay R. Wilde
Oncology | Hematology
Distinguished in Febrile Neutropenia
Dr. Lindsay R. Wilde
Oncology | Hematology

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (53.1 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lindsay Wilde is an Oncologist and a Hematologist in Philadelphia, Pennsylvania. Dr. Wilde is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Febrile Neutropenia, Chronic Familial Neutropenia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Wilde is currently accepting new patients.

Distinguished in Febrile Neutropenia
Dr. Myron E. Bednar
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Myron E. Bednar
Hematology Oncology | Hematology | Oncology

Hunterdon Hematology Oncology, LLC

2100 Wescott Dr, 
Flemington, NJ 
 (21.8 miles away)
908-237-1201
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Myron Bednar is a Hematologist Oncology specialist and a Hematologist in Flemington, New Jersey. Dr. Bednar is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Inflammatory Breast Cancer, Febrile Neutropenia, Familial Colorectal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Bednar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schaar's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile